Anti-Hu CD266 Purified Low Endotoxin

Anti-Hu CD266 Purified Low Endotoxin
Regulatory status
RUO
Antigen
CD266
Clone
ITEM-4
Format
Purified Low Endotoxin
Reactivity
Mouse, Human
Application
WB, FC (QC tested), IHC(F), FUNC
Variant
0.1 mg
12-755-C100
In stock
Variant
0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG2b
Specificity
The mouse monoclonal antibody ITEM-4 recognizes CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.
Application
WB, FC (QC tested), IHC(F), FUNC
Reactivity
Mouse, Human
Immunogen
human CD266-transfected P815 cells
Other names
TWEAKR, FN14, TNFRSF12A
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Low endotoxin azide free phosphate buffered saline (PBS) solution, 0.2 μm filter sterilized. Endotoxin level is less than 0.01 EU/μg of the protein, as determined by the LAL test.
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

Product specific references:

Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108
PubMed
Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. PLoS One. 2012;7(10):e47440.
PubMed
Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8.
PubMed
Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol. 2010 Aug 1;185(3):1593-605.
PubMed
Variant
0.1 mg
12-755-C100
In stock
Variant
0.1 mg
11-261-C100
In stock